AstraZeneca’s immunotherapy combination has missed the mark in certain patients with untreated lung cancer, failing to improve survival compared with standard chemotherapy in a phase 3 tria
The FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in cancer, instead of where the disease originates. <
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
